

APPENDIX A

FIRST REQUEST FOR PRODUCTION:

REQUEST FOR PRODUCTION NO. 4:

All documents and communications referred to in or reviewed or relied upon by the Debtors in connection with, the Plan Projections, including all underlying support and data for the Plan Projections.

- Board presentations and materials:

AMRS-OCUC051329; AMRS-OCUC051364; AMRS-OCUC051391; AMRS-OCUC051680; AMRS-OCUC051699; AMRS-OCUC051817; AMRS-OCUC051862; AMRS-OCUC052060; AMRS-OCUC052141; AMRS-OCUC052172; AMRS-OCUC052441; AMRS-OCUC052865; AMRS-OCUC053030; AMRS-OCUC053146; AMRS-OCUC053317; AMRS-OCUC053615; AMRS-OCUC053740; AMRS-OCUC053854; AMRS-OCUC054014; AMRS-OCUC138833; AMRS-OCUC138847; AMRS-OCUC138917; AMRS-OCUC138935; AMRS-OCUC139055; AMRS-OCUC139076; AMRS-OCUC139193; AMRS-OCUC139273; AMRS-OCUC139662; AMRS-OCUC139720; AMRS-OCUC140146; AMRS-OCUC140319; AMRS-OCUC140320; AMRS-OCUC140321; AMRS-OCUC140322; AMRS-OCUC144149; AMRS-OCUC166877; AMRS-OCUC166878; AMRS-OCUC174764; AMRS-OCUC184985; AMRS-OCUC185130; AMRS-OCUC185485; AMRS-OCUC023352; AMRS-OCUC023421; AMRS-OCUC023430; AMRS-OCUC023525; AMRS-OCUC023560; AMRS-OCUC023612; AMRS-OCUC023627; AMRS-OCUC023633; AMRS-OCUC023646; AMRS-OCUC023667; AMRS-OCUC023677; AMRS-OCUC023791; AMRS-OCUC024085; AMRS-OCUC024223; AMRS-OCUC024278; AMRS-OCUC024308; AMRS-OCUC024333; AMRS-OCUC024340; AMRS-OCUC024360; AMRS-OCUC024377; AMRS-OCUC024452; AMRS-OCUC024969; AMRS-OCUC025117; AMRS-OCUC025247; AMRS-OCUC025379; AMRS-OCUC025405; AMRS-OCUC025412; AMRS-OCUC025571; AMRS-OCUC025614; AMRS-OCUC025631; AMRS-OCUC026025; AMRS-OCUC027028; AMRS-OCUC027079; AMRS-OCUC027165; AMRS-OCUC027171; AMRS-OCUC027374; AMRS-OCUC027406; AMRS-OCUC027426; AMRS-OCUC027620; AMRS-OCUC027738; AMRS-OCUC027851; AMRS-OCUC027852; AMRS-OCUC027949; AMRS-OCUC028407; AMRS-OCUC028950; AMRS-OCUC028969; AMRS-OCUC029423; AMRS-OCUC030041; AMRS-OCUC030268; AMRS-OCUC030426; AMRS-OCUC030509; AMRS-OCUC030532; AMRS-OCUC030971; AMRS-OCUC030987; AMRS-OCUC031051; AMRS-OCUC031080; AMRS-OCUC031251; AMRS-OCUC031384; AMRS-OCUC031422; AMRS-OCUC031469; AMRS-OCUC031620; AMRS-OCUC031827; AMRS-OCUC031845; AMRS-OCUC032576; AMRS-OCUC033166; AMRS-OCUC033192; AMRS-OCUC033521; AMRS-OCUC033794; AMRS-OCUC034124; AMRS-OCUC034418; AMRS-OCUC034591; AMRS-OCUC034592; AMRS-OCUC034593; AMRS-OCUC034594; AMRS-OCUC034595; AMRS-OCUC034596; AMRS-OCUC034597; AMRS-OCUC034598; AMRS-OCUC034599; AMRS-OCUC034600; AMRS-OCUC034601; AMRS-OCUC034602; AMRS-OCUC034603; AMRS-OCUC034604; AMRS-OCUC034605; AMRS-OCUC034606; AMRS-OCUC050199; AMRS-OCUC050358; AMRS-OCUC050739

- AMRS-LAV000718, AMRS-LAV000731 Phoenix – BP Model 12.3.23
- AMRS-LAV000705 Phoenix – BP Model 10.10.23
- AMRS-LAV000744, AMRS-LAV000757 Phoenix – BP Model 8.24.23
- AMRS-LAV000770 Phoenix - Business Plan Update 8.19.23
- AMRS-LAV000805 Phoenix - Updated Five Year Plan Overview 100823
- AMRS-LAV000823 Phoenix Plan Scenario Analysis 082423
- AMRS-LAV000875 Project Phoenix - UCC Presentation 09.01.2023
- AMRS-LAV001026 Phoenix - Updated Five Year Plan Overview 101023

REQUEST FOR PRODUCTION NO. 5:

For the years 2021, 2022, and 2023 year-to-date, the following financial information of the Debtors:

a. Renewable products revenue and gross margin by customer; (the below results are based upon a search of contents for Renewable products revenue)

- AMRS-OCUC091740 Earnings Models (from analysts after Q4 2022 ER on 3.15.23)
- AMRS-OCUC101811 Earnings Models (from analysts after Q4 2022 ER on 3.15.23)
- AMRS-OCUC126772 Q421 Sell Side Estimates - 01.09.21
- AMRS-OCUC143963 Q2 Sell Side Estimates - 05.17.21 - 5 yr
- AMRS-OCUC146426 Q322 Sell Side Estimates - 11.06.22
- AMRS-OCUC148138 Q421 Sell Side Estimates - 11.19.21
- AMRS-OCUC152079 Q322 Sell Side Estimates - 08.30.22
- AMRS-OCUC152721 Q3 Sell Side Estimates - 09.15.21
- AMRS-OCUC158337 Q122 Sell Side Estimates - 05.14.22
- AMRS-OCUC177740 Copy of Q421 Sell Side Estimates - 11.19.21
- AMRS-OCUC183696 Q122 Sell Side Estimates - 05.23.22
- AMRS-OCUC183724 Q122 Sell Side Estimates - 05.09.22
- AMRS-OCUC190637 Q222 Sell Side Estimates - 06.27.22
- AMRS-OCUC191052 Q3 Sell Side Estimates - 08.26.21
- AMRS-OCUC192041 Q2 Sell Side Estimates - 07.20.21
- AMRS-OCUC193077 Q2 Sell Side Estimates - 06.29.21
- AMRS-OCUC195587 Q122 Sell Side Estimates - 04.13.22
- AMRS-OCUC197062 Q122 Sell Side Estimates - 02.23.22
- AMRS-OCUC197063 Q421 Sell Side Estimates - 02.23.22
- AMRS-OCUC200999 Q421 Sell Side Estimates - 01.12.21

b. License and royalty revenue by counterparty

- AMRS-OCUC147224AS-JE01-REV-1022 Record Q3'22 Topside DSM earnout royalty Revenue
- AMRS-OCUC180726 Earnout & Royalty and other agreements dashboard 2.3.2022

c. Detailed sales, general and administrative expense breakdown as internally reported to company management

- AMRS-OCUC046461 Summary AR and AP Agings December 31 2021
- AMRS-OCUC046462 Summary AR and AP Agings June 30 2022
- AMRS-OCUC046463 Summary AR and AP Agings March 31 2022
- AMRS-OCUC046464 Summary AR and AP Agings September 30 2021
- AMRS-OCUC132491 Summary AR and AP Agings March 31 2022
- AMRS-OCUC132498 Summary AR and AP Agings June 30 2022
- AMRS-OCUC145592 Summary AR and AP Agings September 30 2021
- AMRS-OCUC145598 Summary AR and AP Agings December 31 2021
- AMRS-OCUC145599 Summary AR and AP Agings March 31 2022
- AMRS-OCUC145600 Summary AR and AP Agings June 30 2022
- AMRS-OCUC159848 Summary AR and AP Agings March 31 2022
- AMRS-OCUC159855 Summary AR and AP Agings June 30 2022
- AMRS-LAV001023 CBB - AR Aging as of 09.30.23
- AMRS-LAV000966 Amyris - Brands Pro Forma P&Ls
- AMRS-OCUC136229 Breakdown of Invoices for Raw Material and Finished Goods
- AMRS-OCUC145614 March capex
- AMRS-OCUC172388 Pipette NetSuite detail by item
- AMRS-OCUC177738 Prelim Gross Margin Q4
- AMRS-OCUC197471 Prelim Revenue v3
- AMRS-OCUC157623 Opex Data Jun 2022 7.29.22
- AMRS-OCUC151541 Opex Data Aug 2022 - 9.16.22

d. Detailed research & development expense breakdown as internally report to company management

- AMRS-LAV000929 R&D Lab to Market Business Plan 101223 UCC
- AMRS-OCUC141442 R&D - December YTD 2021 Plan vs. Actual - Preliminary
- AMRS-OCUC141443 R&D proposed budget 2022
- AMRS-OCUC144316, AMRS-OCUC148130 - R&D 2021 Cash OpEx Budget
- AMRS-OCUC146279 R&D Sep YTD 2022 Cash OpEx
- AMRS-OCUC146279 R&D Sep YTD 2022 Cash OpEx
- AMRS-OCUC152518 42600-R&D-Program-Management-2021-Cash-OpEx-Budget-Template
- AMRS-OCUC169101 Opex Deep Dive- R&D
- AMRS-OCUC174836 R&D payments

e. Annual gross current and 2022 full year payroll broken down by executive, operations, research & development, sales, and general administrative departments.

Payroll:

- AMRS-LAV000001
- AMRS-LAV000302
- AMRS-LAV000307
- AMRS-LAV000571
- AMRS-LAV000576
- AMRS-LAV000586
- AMRS-LAV000588
- AMRS-LAV000674

REQUEST FOR PRODUCTION NO. 6:

All business plans, financial projections and associated forecast assumptions created during the Time Period relating to the Debtors, including fully functional Microsoft Excel models and related support.

- Board presentations and materials identified in response to RFP No. 1 above
- AMRS-LAV000718, AMRS-LAV000731 Phoenix – BP Model 12.3.23
- AMRS-LAV000705 Phoenix – BP Model 10.10.23
- AMRS-LAV000744, AMRS-LAV000757 Phoenix – BP Model 8.24.23
- AMRS-LAV000770 Phoenix - Business Plan Update 8.19.23
- AMRS-LAV000805 Phoenix - Updated Five Year Plan Overview 100823
- AMRS-LAV000823 Phoenix Plan Scenario Analysis 082423
- AMRS-LAV000875 Project Phoenix - UCC Presentation 09.01.2023
- AMRS-LAV001026 Phoenix - Updated Five Year Plan Overview 101023
- AMRS-LAV001049 Project Cana - 4U by Tia Management Presentation
- AMRS-LAV001078 Project Cana - Biossance Management Presentation
- AMRS-LAV001105 Project Cana - JVN Management Presentation
- AMRS-LAV001121 Project Cana - MenoLabs Management Presentation
- AMRS-LAV001148 Project Cana - Pipette Management Presentation
- AMRS-LAV001185 Project Cana - Rose Inc Management Presentation
- AMRS-LAV001284 Project Cana - Stripes Management Presentation
- AMRS-LAV001311 Project Phoenix Intellectual Property Overview **HIGHLY CONFIDENTIAL**

REQUEST FOR PRODUCTION NO. 7:

All appraisals, valuations, solvency opinions, analyses, PowerPoints, presentations, or other materials created during the Time Period referring or relating to the Debtors' business plans, financial projections, or associated forecast assumptions.

- Duff & Phelps Reports AMRS-OCUC128861; AMRS-OCUC128873

- AMRS-LAV000993 Amyris - IP Valuation - As of 08302019 v09232019p2 Collateral
- AMRS-LAV001003 Amyris - Strategic IP Valuation - As of 08302019 v10172019 Market
- AMRS-LAV001349 Amyris IP List - PATENTS (as of March 5, 2019)
- AMRS-LAV001399 Amyris IP List - TRADEMARKS (as of March 5, 2019)
- AMRS-LAV001406 Domains as of 2023-11-0
- AMRS-LAV001407 Patents as of 2023-11-02

REQUEST FOR PRODUCTION NO. 8:

All documents and communications referring or relating to the value of the collateral subject to Lavvan's liens

- AMRS-LAV001049 Project Cana - 4U by Tia Management Presentation
- AMRS-LAV001078 Project Cana - Biossance Management Presentation
- AMRS-LAV001105 Project Cana - JVN Management Presentation
- AMRS-LAV001121 Project Cana - MenoLabs Management Presentation
- AMRS-LAV001148 Project Cana - Pipette Management Presentation
- AMRS-LAV001185 Project Cana - Rose Inc Management Presentation
- AMRS-LAV001284 Project Cana - Stripes Management Presentation
- AMRS-OCUC027171 Amyris Q1, 2023 CFO Memo, May 12, 2023,
- AMRSOCUC023560 Amyris, "Restructuring Committee Meeting," August 29, 2023
- AMRS-LAV000966 Amyris - Brands Pro Forma P&Ls
- AMRS-LAV000718, AMRS-LAV000731 Phoenix – BP Model_12.3.23
- AMRS-LAV001024 Consumer Brands Inventory Summary – September 2023 vDataroom
- AMRS-LAV000705 Phoenix – BP Model_10.10.23.
- AMRS-LAV001023 CBB - AR Aging as of 09.30.23
- AMRS-LAV000744, AMRS-LAV000757 Phoenix – BP Model_8.24.23

SECOND REQUEST FOR PRODUCTION

REQUEST FOR PRODUCTION NO. 1:

The final (or, if not yet finalized, the most recent drafts of the) amended or modified agreements regarding the Debtors' commercial relationships with each of DSM and Givaudan.

- AMRS-LAV000967 Amyris - DSM-Firmenich Term Sheet (Fully Executed)